Patients’ Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status

References

1. ↵
   Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. J Clin Invest 2007; 117: 2351–61.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Etzioni R, Penson D, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981–90.

   OpenUrlAbstract/FREE Full Text
3. ↵
   Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006; 98: 1134–41.

   OpenUrlAbstract/FREE Full Text
4. ↵
   Harlan SR, Cooperberg MR, Elkin EP, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003; 170: 1804–7.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Parker C, Muston D, Melia J, Moss S, Dearnely D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006; 94: 1361–8.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Fowler FJ, Collins MM, Albertsen PC, Zeitman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of localized prostate cancer. JAMA 2000; 283: 3217.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians’ estimates of life expectancy in patients with localized prostate cancer. Urology 2002; 60: 258–63.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: prostate cancer. Available from http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed 25 January 2009.
9. ↵
   Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 2006; 106: 1865–74.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005; 23: 2772–80.

    OpenUrlAbstract/FREE Full Text
11. ↵
    Hu JC, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. J Urol 2003; 169: 2279–83.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25: 3576–81.

    OpenUrlAbstract/FREE Full Text
13. ↵
    Wilson JRM, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life expectancy: how accurate are urologists and oncologists? BJU Int 2005; 95: 794–8.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Bass PF, Wilson JF, Griffith CH. A shortened instrument for literacy screening. J Gen Intern Med 2003; 18: 1036–8.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    Hoffman RM, Stone SM, Espey D, Potosky A. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 2005; 5: 27.

    OpenUrlCrossRefPubMed
16. ↵
    Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285: 2750–6.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Post PN, Hansen BE, Kil PJM, Coebergh JWW. The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. BJU Int 2001; 87: 821–6.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Ware JE, Kosinki M. SF-36 Physical and Mental Health Summary Scales: a manual for users of version 1, 2nd ed. Lincoln (RI): QualityMetric, Inc.; 2005.
19. ↵
    Litwin M, Hays RD, Fink A, Ganz PA, Leake B, Brooke RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36: 1002–12.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status Index). Am J Cardiol 1989; 64: 651–4.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand 1983; 67: 361–70.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Mehta SS, Lubeck DP, Pasta DJ, Litwin M. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol 2003; 170: 1931–3.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Sherbourne CD, Stewart AL. The MOS Social Support Survey. Soc Sci Med 1991; 32: 705–14.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    Bowling A. Measuring health: a review of quality of life measurement scales, 2nd ed. Buckingham (UK): Open University Press; 1997.
25. ↵
    Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Caroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141–9.

    OpenUrlAbstract/FREE Full Text
26. ↵
    Jang TL, Yossepowitch O, Bianco FJ, Scardino PT. Low risk prostate cancer in men under age 65: the case for definitive treatment. Urol Oncol 2007; 25: 510–4.

    OpenUrlPubMedWeb of Science
27. ↵
    Draisma G, Boer R, Otto SJ, et al. Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868–78.

    OpenUrlAbstract/FREE Full Text
28. ↵
    Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23: 8165–9.

    OpenUrlAbstract/FREE Full Text
29. ↵
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095–101.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713–9.

    OpenUrlCrossRefPubMedWeb of Science
31. ↵
    Alibhai SM, Klotz LH. A systematic review of randomized trials in localized prostate cancer. Can J Urol 2004; 11: 2110–7.

    OpenUrlPubMed
32. ↵
    Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–84.

    OpenUrlCrossRefPubMedWeb of Science
33. ↵
    Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296: 2683–93.

    OpenUrlCrossRefPubMedWeb of Science
34. ↵
    Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. Urology 2004; 63: 103–9.

    OpenUrlCrossRefPubMedWeb of Science
35. ↵
    Dugan JA, Bostwick DG, Myers RP, Qian J, Bregstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288–94.

    OpenUrlCrossRefPubMedWeb of Science
36. ↵
    Cohen H, Britten N. Who decides about prostate cancer treatment? A qualitative study. Fam Pract 2003; 20: 724–9.

    OpenUrlAbstract/FREE Full Text
37. ↵
    Mohan R. Family physicians could help in predicting life expectancy without prostate cancer. J Clin Oncol 2008; 26: 690–1.

    OpenUrlFREE Full Text
38. ↵
    Fagerlin A, Rovner D, Stableford S, Jentoft C, Wei JT, Holmes-Rovner M. Patient education materials about the treatment of early stage prostate cancer: a critical review. Ann Intern Med 2004; 140: 721–8.

    OpenUrlCrossRefPubMedWeb of Science
39. ↵
    Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med 2007; 33: 428–34.

    OpenUrlCrossRefPubMedWeb of Science
40. ↵
    Guerra CE, Jacobs SE, Holmes JH, Shea JA. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. J Gen Intern Med 2007; 22: 901–7.

    OpenUrlCrossRefPubMedWeb of Science
41. ↵
    Visser A, van Andel G. Psychosocial and educational aspects in prostate cancer patients. Patient Educ Couns 2003; 49: 203–6.

    OpenUrlPubMed
42. ↵
    American Urological Association. Member profile. October 2008. Available from http://www.auanet.org/content/about-us/members/membersprofile.pdf. Accessed 28 January 2009.